|Bid||152.98 x 100|
|Ask||153.00 x 300|
|Day's Range||152.66 - 154.60|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||14.51|
|Dividend & Yield||4.60 (2.94%)|
|1y Target Est||N/A|
A leading competitor's osteoporosis drug encountered serious side effects in a late stage trial.
Nothing is going right for Amgen these days. It now says its experimental osteoporosis treatment, Evenity, is unlikely to win approval from the Food and Drug Administration this year.
NEW YORK (AP) — U.S. stocks are higher Monday as software and chip makers and other technology companies climb. Defense contractors are also rising as the market bounces back from a turbulent week. Ford is up after it replaced CEO Mark Fields.